Investor Presentaiton
Hematology
Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
GPRC5D CAR T in post-BCMA patients shows compelling
efficacy and differentiated safety
ORR = 96.3%¹
100
SCR
On-target/off-tumor TRAES, n (%)
Any grade
90
■ CR
Skin
14 (20.9)
All treated patients (n = 67)
Grade > 3
0 (0)
80
ORR = 76%¹
29.6
CRR
VGPR
Dysgeusia/taste disorder
12 (17.9)
0 (0)
40.7%
PR
70
Nails
6 (9.0)
0 (0)
Response, %
60
32.0
CRR
11.1
Dysphagia
1 (1.5)
0 (0)
36%
50
Neurotoxicity, n (%)
4.0
ICANS-type neurotoxicity
7 (10.4)
2 (3.0)
40
33.3
Dizziness
7 (10.4)
1 (1.5)
30
32.0
Headache
7 (10.4)
0
20
Ataxia
10
22.2
2 (3.0)
0
8.0
Neurotoxicity
2 (3.0)
0
0
Gait disturbance
Prior BCMA
(n=25)
No prior BCMA
(n=27)
1 (1.5)
0
Dysarthria
1 (1.5)
Non-hematologic, n (%)
Patients with prior BCMA-targeted therapy¹, n (%)
CAR T-cell therapy
(cilta-cel, ide-cel, orva-cel, ALLO 715, others not specified)
Non-CAR T-cell therapy
(ADC, belantamab mafodotin, TCE)
n = 25
CRS
58 (86.6)
3 (4.5)
19 (76)
8 (32)
GPRC5D CAR T on-target/off-tumor safety profile
differentiated from bispecifics with lower rates of any grade
events, and no Grade ≥ 3 events
1. Bal S, et al. EHA 2023 [Presentation #S193].
Ill Bristol Myers Squibb™
Not for Product Promotional Use
88View entire presentation